Celgene Corporation's competitors
Celgene Corporation's competitors include Gilead Sciences, Amgen, Shire and Eiger BioPharmaceuticals
Add company...
You can compare up to 12 companies. Please remove a company to add a new one
| Save ComparisonClear all |  Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. |  Amgen Amgen engages in the development of human therapeutic products in supportive of cancer care, inflammation, nephrology and bone diseases. |  Eiger BioPharmaceuticals Eiger is a biopharmaceutical company developing new antiviral agents against novel targets in the treatment of hepatitis. | ||
Founding Date | Founding Date 1986 | Founding Date 1987 | Founding Date 1980 | Founding Date 1986 | Founding Date 2008 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Summit, US HQ Singapore, SG Boudry, CH | Locations Foster City, US HQ Fremont, US Oceanside, US San Dimas, US Branford, US Seattle, US | Locations Thousand Oaks, US HQ Sydney, AU North Ryde, AU Vienna, AT Brussels, BE São Paulo, BR Burnaby, CA see more | Locations Dublin, IE HQ Buenos Aires, AR Sydney, AU Wien, AT Bruxelles, BE Chácara Santo Antonio (Zona Sul), BR Sofia, BG see more | Locations Palo Alto, US HQ |
Employees | Employees 7,467 5% increase | Employees 9,000 | Employees 20,800 8% increase | Employees 23,044 4% decrease | Employees 17 15% decrease |
Valuation ($) | Valuation ($) 72.4 b | Valuation ($) 97.6 b | Valuation ($) 128.4 b | Valuation ($) 42.4 b | Valuation ($) 93.3 m |
Facebook likes | Facebook likes 6.6 k | Facebook likes 5.4 k | Facebook likes N/A | Facebook likes N/A | Facebook likes N/A |
Twitter followers | Twitter followers 19.1 k | Twitter followers 27 k | Twitter followers 65.4 k | Twitter followers 6.2 k | Twitter followers N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $13b (FY, 2017) | Revenue (est.) $26.1b (FY, 2017) | Revenue (est.) $23b (FY, 2016) | Revenue (est.) $15.2b (FY, 2017) | Revenue (est.) N/A |
Cost of goods | Cost of goods $461m (FY, 2017) | Cost of goods $4.4b (FY, 2017) | Cost of goods $4.2b (FY, 2016) | Cost of goods $4.7b (FY, 2017) | Cost of goods N/A |
Gross profit | Gross profit $12.5b (FY, 2017) | Gross profit $21.7b (FY, 2017) | Gross profit $18.8b (FY, 2016) | Gross profit $10.5b (FY, 2017) | Gross profit N/A |
Net income | Net income $2.9b (FY, 2017) | Net income $4.6b (FY, 2017) | Net income $7.7b (FY, 2016) | Net income $4.3b (FY, 2017) | Net income ($42.4m) (FY, 2017) |
Operating ⚠ | |||||
Countries | Countries N/A | Countries 30 (FY, 2016) | Countries N/A | Countries 100 (FY, 2017) | Countries N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 3 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products 7 (FY, 2017) | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 12 (FY, 2016) | Phase II Trials Products N/A | Phase II Trials Products 10 (FY, 2017) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 6 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products 15 (FY, 2017) | Phase III Trials Products N/A |
For sources of this data, please see the company profileDownload Excel